MedTrace Logo

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

NCT03647423 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2025-02-21

No results posted yet for this study

Summary

QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.

Conditions

  • Chordoma
  • Unresectable Malignant Neoplasm

Interventions

BIOLOGICAL

Aldoxorubicin Hydrochloride

Aldoxorubicin Hydrochloride HCI

BIOLOGICAL

ALT-803

Recombinant human super agonist interleukin-15 (IL-15) complex

BIOLOGICAL

ETBX-051

Ad5 \[E1-, E2b-\]-Brachyury

BIOLOGICAL

ETBX-061

Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]

BIOLOGICAL

GI-6301

Brachyury yeast

BIOLOGICAL

haNK

haNK™, NK-92 \[CD16.158V, ER IL-2\]

DRUG

Avelumab

injection

DRUG

Cetuximab

Injection

DRUG

Cyclophosphamide

Capsules

RADIATION

SBRT

Stereotactic body radiation therapy

Sponsors & Collaborators

  • ImmunityBio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2020-08-31
Completion
2021-12-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647423 on ClinicalTrials.gov